top of page
company0.jpg

About

Genomic NantiJen Diagnostics

Genomic NantiJen Diagnostics is a healthcare company based in the United States, we operate in the US and Hong Kong under two divisions: Biopharmaceuticals and Diagnostics. Genomic NantiJen Diagnostics is a privately held company headquartered in Dover, USA.

​

Genomic NantiJen Diagnostics researches, develops, manufactures bacterial and viral diagnostic kits, reagents, reference standards for research and medical diagnostic applications. Internally, it is organized into two business divisions:

​

Biopharmaceuticals Biologics:

  • Stem sells

  • Vaccines (Viral Vaccines, Bacterial Vaccines, Conjugate Vaccines, Viral Particles, DNA and RNA Based Vaccines).

  • Novacell proprietary Platform Technology for making affordable, timely available and readily accessible vaccines with the highest titers and purest quality standards

  • R& D, Process Development, Scale-up and Clinical Development                                                                                                 

Diagnostics (CLIA, CAP, ISO & Medical Research Centers)

  • Molecular Diagnostics; RT-PCR, RNA, DNA PCR

  • Tissue Diagnostics                                                                                    

All business areas focus on health care applications, targeting physicians, hospitals, government contracts, clinics, or consumers. Life Science targets research settings in academia and pharmaceutical and biotechnology industries.

科學研究員
科學

Our History in science and innovation 

​

Dr. Niranjan Kumar leads Genomic NantiJen Diagnostics research and invention team, he was the first to develop and validate the amplification of RNA in In Vitro (Peripheral Blood Mononuclear Cells) and In Vivo (Lung Tissue) in 1996. Dr. Kumar’s innovative technique of RT-PCR in tissue and in the cell was well-received, presented and published in the International Conference (ASC, 1995) and Peer Reviewed Journals.

​

Since then there were number of publications using this technique for developing novel diagnostics at the gene level.

​

Dr. Kumar developed quantitative RT-PCR, multiple gene amplification in one reaction/one tube. These genes were normalized against the control gene and quantified. Dr. Kumar’s work was published in the peer-reviewed journals.

​

Genomic NantiJen Diagnostics is actively in search of identifying and quantifying various emerging pathogenic viruses and bacteria at RNA/DNA and protein levels. Our scientists, clinicians and laboratory technicians work collaboratively to develop and validate the methods/tests for research, diagnostics and biopharmaceutical applications. Our extensive (collectively over 60 years) experience has positioned us as the most innovative, precise and quality diagnostic & biopharmaceutical product developers and service providers.

​

Our test methods are

  • Cell Biology

  • Molecular Biology

  • Toxicology

  • Immunology

  • Biochemistry

bottom of page